Procyrion develops technology solutions and offers a catheter-based circulatory support technologies.
Procyrion develops technology solutions and offers a catheter-based circulatory support technologies. One in five adults over the age of 40 will develop heart failure in his or her lifetime. For the sickest patients, only 1% receive treatment annually due to scarcity, cost, and high risk of current solutions.Procyrion, has developed a solution: Aortix is a circulatory support pump implanted without surgery. Thinner than a #2 pencil, a cardiologist can implant Aortix through a catheter in the leg, deploying it between the heart and the kidneys to unload the failing heart and perfuse vital organs. This first-in-class device allows the heart to rest and heal while correcting the fluid imbalance.The company was founded in 2005 and is based in Houston, Texas.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jan 31, 2018 | Series C | $16M | 1 | Aquinas | — | Detail |